ADMELOG (INSULIN LISPRO)
ADMELOG (INSULIN LISPRO) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: ADMELOG; Generic name: INSULIN LISPRO; Drug class: Insulin Analog [EPC].
| Brand name | ADMELOG |
|---|---|
| Generic name | INSULIN LISPRO |
| Drug class | Insulin Analog [EPC] |
| Manufacturer | Sanofi-Aventis U.S. LLC |
| Used for | 1 INDICATIONS AND USAGE ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION See Full Prescribing Information for important preparation and administration instructions. ( 2.1 , 2.2 , 2.3 , 2.4 ) Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.2 ) Subcutaneous injection ( 2.2 ): Administer ADMELOG by subcutaneous injection into the abdominal wall, thigh, upper arm, or buttocks within 15 minutes before a meal or immediately after a meal. Rotate injection sites to reduce risk of lipodystrophy and lo |
| Active ingredient(s) | INSULIN LISPRO |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0691def8-4a7b-4de3-866f-a280989f47f1 |